The Joint Meeting of the American Academy of Sleep Medicine and Sleep Research Society (SLEEP)

A recent study presented at SLEEP 2024 showed that depression in patients with isolated REM sleep behavior disorder significantly increased the risk of conversion to neurodegenerative diseases.

Those on low-sodium oxybate, regardless of psychiatric comorbidity status, outperformed placebo on a number of outcomes, including Epworth Sleepiness Scale and weekly cataplexy attacks.

A majority of the small cohort of patients with SMA did not need a polysomnogram at 1 year because respiratory pathology was not a concern, attributable to improvements from disease-modifying therapies.

After 5 weeks of open-label treatment, KP1077-treated patients showed mild adverse events that were typical for a central nervous system stimulant.

The duo from Indiana University School of Medicine discussed the ongoing research initiatives to better understand sleep disorders among pediatrics, and ways to improve approaches like cognitive behavioral therapy. [WATCH TIME: 4 minutes]

The undergraduate program director at the University of South Carolina discussed outdated teaching methods used in neurology, and the need to provide different hands-on approaches to students. [WATCH TIME: 5 minutes]

The duo from Indiana University School of Medicine provided perspective on the reasons for why cognitive behavioral therapy used for insomnia need to be adjusted in adolescents with the sleep disorder. [WATCH TIME: 3 minutes]

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital provided perspective on the current major research priorities for the treatment of restless legs syndrome. [WATCH TIME: 3 minutes]

The professor of neurology at UMass Chan School of Medicine discussed the various impacts Daylight Savings Time has on sleep quality and overall health in children and adolescents. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Amit Bar-Or, MD; Gavin Giovannoni, MBBCh, PhD; Dayna Johnson, PhD, MPH, MSW, MS; John Winkelman, MD, PhD; Laxman Bahroo, DO; Ling Wan-Albert, OTD, OTR/L; Sara Pavitt, MD; and Ali Ezzati, MD. [LISTEN TIME: 28 minutes]

The undergraduate program director at the University of South Carolina provided perspective on the factors that go into building an equitable and effective medical course for young medical professionals. [WATCH TIME: 5 minutes]

The associate professor at Johns Hopkins School of Nursing provided insight on a presentation at SLEEP 2023, and whether neurofilament light should be more considered when assessing elderly patients with sleep disorders. [WATCH TIME: 5 minutes]

Marisa Whalen, PharmD, associate director of Medical Affairs at Jazz Pharmaceuticals, discussed presentations at SLEEP 2023 on the real-world burdens of idiopathic hypersomnia and the smooth transition to low sodium oxybate in patients with narcolepsy.

The sleep epidemiologist and assistant professor at the Rollins School of Public Health at Emory University discussed the multi-level effort needed to improve sleep issues seen in individuals most impacted by social determinants of health. [WATCH TIME: 3 minutes]

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital discussed the benefits opioids have for patients with restless legs syndrome, as well as how they can be safely used as part of treatment strategies. [WATCH TIME: 4 minutes]

Garth T. Whiteside, PhD, head of preclinical development at Imbrium Therapeutics, discussed a phase 2 clinical study that explored the use of sunobinop in patients with insomnia during recovery from alcohol use disorder.

The professor of neurology at UMass Chan School of Medicine provided perspective on the benefits of pushing back school start times based on what research has shown.

In a secondary analysis of a double-blind trial, mazindol extended-release outperformed placebo on clinician and patient scales of cataplexy severity and excessive daytime sleepiness.

Over a 5-year period in a study, both insomnia protective and risk factors in adults were observed as significantly associated with the sleep disorder, offering valuable insights for prevention strategies.

John Harsh, PhD, clinical research director, Colorado Sleep Institute, sat down at SLEEP 2023 to discuss the RESTORE study results, and why patients with narcolepsy appear to prefer once-nightly sodium oxybate.

The sleep epidemiologist and assistant professor at the Rollins School of Public Health at Emory University, insight on the associations between race, socioeconomic backgrounds, and poor sleep and insufficient sleep. [WATCH TIME: 2 minutes]

Patients given slow oscillatory transcranial direct current stimulation during sleep recalled significantly more words 2 hours post-awakening compared with the sham group.

Patients on twice-nightly oxybate reported more issues with inconvenience, anxiety, and feeling somewhat, quite a bit, or extremely groggy/unsteady the next morning.

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital provided insight on new updates to the management of restless legs syndrome, including removing dopamine agonists as first line treatments. [WATCH TIME: 8 minutes]

At the conclusion of the analysis, lemborexant was shown to be safe, with significant improvements seen in REM latency, total REM sleep, and other measures.

Preclinical findings show the potential of samelisant, a potent and orally active Histamine H3 receptor inverse agonist, as a potential treatment for patients with Parkinson disease who experience excessive daytime sleepiness.

According to a recent study presented at SLEEP 2023, the decline in MOCA scores in patients with mild cognitive impairment was associated with the degree of hypoxia observed from sleep studies.

The chief medical officer of Harmony Biosciences provided perspective on a proof-of-concept study assessing pitolisant’s (Wakix) clinical benefit in reducing excessive daytime sleepiness individuals with Prader-Willi syndrome.

At the conclusion of the 6-week treatment period, preliminary analyses suggested a greater trend toward improvement on subjective measures of insomnia compared with objective sleep measures.

The pediatric neurologist and sleep medicine specialist at Geisinger Medical Center provided commentary on the current unmet needs for patients with narcolepsy, including improvements in treatment options. [WATCH TIME: 3 minutes]